From the source
OpenAI has acquired drug development software startup Orchestra Bio and folded its staff and technology into OpenAI's Rosalind life sciences unit.
- Orchestra builds AI agents that help pharmaceutical teams keep development programs on track, monitoring studies and, per TechCrunch's write-up of the deal, tracking finances and sorting out clinical trial scheduling problems.
- OpenAI's case for the deal rests on how long drugs take to reach patients: by its count, U.S. regulatory approval takes 10 to 15 years on average, and programs pass between departments and outside partners whose systems often do not connect.
- In OpenAI's telling, a failed manufacturing batch that threatens to push a trial back would set the software to work out which activities and timelines are hit and weigh ways to respond, though people still make the final call.
- Terms were not disclosed, and OpenAI gave no timeline for when Orchestra's agents will show up in its products.
- The Rosalind business dates to April, when GPT-Rosalind launched as a reasoning model for biology and drug discovery research, and eligible organizations have been able to use it outside research preview since September under a trusted-access program.
- Novo Nordisk and Moderna are among the drugmakers already working with OpenAI on Rosalind, and the deal follows Torch Health joining OpenAI in January to build out ChatGPT Health.